A cost-effective innovation in anaemia management for paediatric patients with haemodialysis-dependent chronic kidney disease.

ABSTRACT:

Background

Paediatric patients undergoing haemodialysis typically require intravenous (IV) iron therapy to replenish iron stores. Upon establishing our home haemodialysis service, the need for an efficient IV iron administration method prompted exploration beyond the conventional use of iron sucrose, which is associated with anaphylaxis and requires frequent infusions. Ferric carboxymaltose has a favourable safety profile and corrects iron deficiency with less frequent infusions. We aimed to establish if ferric carboxymaltose was a viable alternative in this patient group.

Methods

This single-centre, uncontrolled retrospective cohort study assessed the effectiveness of ferric carboxymaltose in maintaining laboratory parameters (haemoglobin level, transferrin saturation and r

SUBMITTER: Preston R 

PROVIDER: S-EPMC12116716 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature